| Recruiting | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Vers Chronic Graft-versus-host-disease | Phase 2 | 2026-05-31 |
| Recruiting | Study of INCA036978 in Participants With Myeloproliferative Neoplasms Myeloproliferative Neoplasms | Phase 1 | 2026-04-27 |
| Recruiting | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metasta Solid Tumors | Phase 3 | 2026-04-09 |
| Active Not Recruiting | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Int Healthy Participants | Phase 1 | 2026-03-19 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without I CRC (Colorectal Cancer) | Phase 3 | 2026-03-05 |
| Recruiting | Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidr Hidradenitis Suppurativa (HS) | Phase 2 | 2026-02-02 |
| Recruiting | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies Solid Tumors, Hematologic Malignancies | Phase 1 | 2026-01-08 |
| Recruiting | Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Immune Thrombocytopenia | Phase 2 | 2025-12-29 |
| Recruiting | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resist Ovarian Cancer | Phase 3 | 2025-12-09 |
| Completed | Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INC Healthy Participants | Phase 1 | 2025-11-13 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonseg NonSegmental Vitiligo | Phase 3 | 2025-11-13 |
| Recruiting | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Ovarian Cancer | Phase 2 | 2025-11-12 |
| Recruiting | Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Hidradenitis Suppurativa | Phase 1 | 2025-11-03 |
| Recruiting | A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms Myeloproliferative Neoplasms | Phase 1 | 2025-10-01 |
| Terminated | Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healt Healthy Participants | Phase 1 | 2025-07-28 |
| Completed | A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetic Healthy Participants | Phase 1 | 2025-07-16 |
| Active Not Recruiting | A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | 2025-06-30 |
| Completed | A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis, Healthy Volunteers | — | 2025-06-27 |
| Recruiting | A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD Chronic Graft-versus-host-disease | Phase 1 / Phase 2 | 2025-06-25 |
| Recruiting | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa ( Hidradenitis Suppurativa | Phase 3 | 2025-06-23 |
| Recruiting | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old Atopic Dermatitis | Phase 3 | 2025-06-17 |
| Recruiting | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa ( Hidradenitis Suppurativa | Phase 3 | 2025-06-12 |
| Active Not Recruiting | A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Di Chronic Graft-versus-host-disease | Phase 3 | 2025-06-04 |
| Completed | A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally Healthy Volunteers | Phase 1 | 2025-05-12 |
| Recruiting | A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluat Healthy Participants | Phase 1 | 2025-05-05 |
| Recruiting | A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolat Graft-versus-host Disease (GVHD) | Phase 3 | 2025-04-02 |
| Active Not Recruiting | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutatio Solid Tumors | Phase 1 | 2025-03-27 |
| Recruiting | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib Hidradenitis Suppurativa (HS) | Phase 3 | 2025-02-28 |
| Completed | Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Participants | Phase 1 | 2025-02-13 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental V NonSegmental Vitiligo | Phase 3 | 2025-01-24 |
| Recruiting | A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Chronic Graft-versus-host-disease | Phase 3 | 2025-01-21 |
| Completed | A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Part Healthy Participants | Phase 1 | 2025-01-14 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Chronic Graft-versus-host-disease | Phase 2 | 2024-10-11 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP Prurigo Nodularis | Phase 3 | 2024-10-10 |
| Recruiting | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP Prurigo Nodularis | Phase 3 | 2024-10-10 |
| Completed | A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Healthy Participants | Phase 1 | 2024-09-25 |
| Completed | A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administratio Healthy Participants | Phase 1 | 2024-08-12 |
| Recruiting | A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms Myeloproliferative Neoplasms | Phase 1 | 2024-08-08 |
| Completed | A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants Healthy Participants | Phase 1 | 2024-07-12 |
| Completed | A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Healthy Participants | Phase 1 | 2024-06-19 |
| Completed | A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]IN Healthy Participants | Phase 1 | 2024-05-15 |
| Completed | A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethiny Healthy Participants | Phase 1 | 2024-05-07 |
| Completed | A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermati Atopic Dermatitis | Phase 3 | 2024-04-26 |
| Terminated | A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 / Phase 2 | 2024-04-16 |
| Completed | A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ru Healthy Participants | Phase 1 | 2024-03-26 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to H Healthy Participants | Phase 1 | 2024-03-14 |
| Completed | A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream Prurigo Nodularis | Phase 1 | 2024-02-27 |
| Active Not Recruiting | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | Phase 3 | 2024-01-30 |
| Recruiting | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutatio Solid Tumors | Phase 1 | 2024-01-04 |
| Terminated | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Advanced Solid Tumors | Phase 1 | 2023-12-28 |
| Recruiting | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participant Myeloproliferative Neoplasms | Phase 1 | 2023-12-04 |
| Active Not Recruiting | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) NonSegmental Vitiligo | Phase 3 | 2023-11-29 |
| Active Not Recruiting | A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) NonSegmental Vitiligo | Phase 3 | 2023-11-27 |
| Active Not Recruiting | A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Na Advanced Solid Tumor | Phase 2 | 2023-10-30 |
| Active Not Recruiting | A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma | Phase 2 | 2023-10-09 |
| Recruiting | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participant Myeloproliferative Neoplasms | Phase 1 | 2023-09-25 |
| Recruiting | Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed Pregnancy Related, Atopic Dermatitis | — | 2023-09-13 |
| Terminated | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) | Phase 1 | 2023-08-29 |
| Recruiting | Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease cGVHD | — | 2023-08-01 |
| Completed | Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria | Phase 2 | 2023-07-31 |
| Completed | Topical Ruxolitinib Evaluation in Chronic Hand Eczema Hand Eczema | Phase 2 | 2023-07-31 |
| Recruiting | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | 2023-07-24 |
| Recruiting | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Phase 2 | 2023-07-11 |
| Completed | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Prurigo Nodularis | Phase 3 | 2023-06-12 |
| Completed | A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo Nonsegmental Vitiligo With Genital Involvement | Phase 2 | 2023-04-11 |
| Recruiting | An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolit Pregnancy Related, Atopic Dermatitis | — | 2023-03-27 |
| Terminated | The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Exp Atopic Dermatitis | Phase 4 | 2023-03-16 |
| Completed | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) Prurigo | Phase 3 | 2023-03-10 |
| Completed | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Seve Hidradenitis Suppurativa (HS) | Phase 3 | 2023-02-22 |
| Withdrawn | Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 Chronic Hand Eczema (CHE) | Phase 3 | 2023-01-31 |
| Withdrawn | Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 Hand Eczema | Phase 3 | 2023-01-31 |
| Completed | Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal Renal Insufficiency, Kidney Diseases | Phase 1 | 2023-01-12 |
| Completed | Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies Advanced Malignancies | Phase 1 | 2023-01-05 |
| Withdrawn | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphom Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) | Phase 3 | 2022-12-30 |
| Active Not Recruiting | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Re Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 3 | 2022-12-23 |
| Completed | A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Seve Hidradenitis Suppurativa (HS) | Phase 3 | 2022-12-19 |
| Completed | A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function Renal Insufficiency, Kidney Diseases | Phase 1 | 2022-12-08 |
| Completed | Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativ Hidradenitis Suppurativa | Phase 2 | 2022-12-07 |
| Completed | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus Cutaneous Lichen Planus | Phase 2 | 2022-11-23 |
| Completed | A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus Lichen Sclerosus | Phase 2 | 2022-11-18 |
| Recruiting | Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled Hematologic Malignancies | Phase 2 | 2022-11-08 |
| Completed | Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis Atopic Dermatitis (AD) | Phase 3 | 2022-09-01 |
| Active Not Recruiting | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R- Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | 2022-07-19 |
| Recruiting | Study of INCB123667 in Subjects With Advanced Solid Tumors Solid Tumors | Phase 1 | 2022-07-05 |
| Terminated | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Glioblastoma, Adult-type Diffuse Gliomas | Phase 2 | 2022-05-20 |
| Recruiting | To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Fibrodysplasia Ossificans Progressiva (FOP) | Phase 2 | 2022-05-05 |
| Completed | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitili Vitiligo | Phase 2 | 2022-05-05 |
| Completed | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | 2022-04-29 |
| Terminated | Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase 3 | 2022-03-15 |
| Withdrawn | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With New Mantle Cell Lymphoma | Phase 3 | 2022-03-11 |
| Completed | A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-I Healthy Volunteers | Phase 1 | 2022-01-21 |
| Terminated | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoa Urothelial Carcinoma | Phase 2 | 2022-01-14 |
| Completed | Study of Ruxolitinib Cream in Children With Atopic Dermatitis Atopic Dermatitis | Phase 1 | 2021-12-16 |
| Completed | Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impair Renal Impairment, Hemodialysis | Phase 1 | 2021-12-14 |
| Completed | Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement Atopic Dermatitis | Phase 2 | 2021-11-10 |
| Completed | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis Prurigo Nodularis | Phase 2 | 2021-11-04 |
| Completed | The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic De Atopic Dermatitis | Phase 2 | 2021-10-12 |
| Terminated | Study of INCA 0186 in Subjects With Advanced Solid Tumors Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies | Phase 1 | 2021-10-04 |
| Recruiting | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in P Diffuse Large B-cell Lymphoma | — | 2021-09-20 |
| Terminated | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refra Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | 2021-09-16 |
| Terminated | Study of INCB086550 in Select Solid Tumors Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma | Phase 2 | 2021-09-02 |
| Terminated | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myelodysplastic Syndromes, Multiple Myeloma, Anemia | Phase 1 / Phase 2 | 2021-08-19 |
| Completed | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) Atopic Dermatitis | Phase 3 | 2021-07-19 |
| Completed | To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With P Myelofibrosis, Polycythemia Vera, Thrombocythemia | Phase 2 | 2021-07-12 |
| Terminated | The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. Advanced Malignancies | Phase 2 | 2021-07-08 |
| Completed | A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA) Vitiligo | Phase 2 | 2021-06-23 |
| Terminated | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Sub Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis | Phase 3 | 2021-05-26 |
| Terminated | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis | Phase 3 | 2021-05-24 |
| Active Not Recruiting | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Pat Diffuse Large B-cell Lymphoma | Phase 3 | 2021-05-11 |
| Completed | A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo NonSegmental Vitiligo | Phase 2 | 2021-05-06 |
| Completed | To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Re Advanced Malignancies | Phase 1 | 2021-05-04 |
| Active Not Recruiting | A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Place Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | 2021-04-15 |
| Completed | To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Advanced Malignancies | Phase 1 | 2021-03-29 |
| Terminated | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma | Phase 1 | 2021-03-26 |
| Active Not Recruiting | INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | 2021-03-19 |
| Active Not Recruiting | A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease | Phase 2 | 2021-03-10 |
| Active Not Recruiting | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neop Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome | Phase 1 | 2021-02-23 |
| Completed | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer | Phase 1 | 2021-02-03 |
| Active Not Recruiting | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants Endometrial Cancer | Phase 2 | 2021-01-26 |
| Completed | Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamo Squamous Cell Carcinoma of the Anal Canal | Phase 3 | 2021-01-12 |
| Completed | Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo Vitiligo | Phase 3 | 2020-09-24 |
| Active Not Recruiting | Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer | Phase 3 | 2020-09-11 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma | Phase 1 | 2020-09-04 |
| Completed | To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa Hidradenitis Suppurativa, Acne Inversa | Phase 2 | 2020-08-25 |
| Active Not Recruiting | Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in B-Cell Malignancies | Phase 2 | 2020-08-03 |
| Withdrawn | INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1 Non-small Cell Lung Cancer | Phase 3 | 2020-07-31 |
| Completed | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM Melanoma | Phase 1 / Phase 2 | 2020-07-27 |
| Terminated | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mec COVID-19 | Phase 3 | 2020-05-24 |
| Terminated | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 2 | 2020-05-14 |
| Completed | A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy Cytokine Release Syndrome | Phase 2 | 2020-02-07 |
| Terminated | Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transp Bronchiolitis Obliterans Syndrome | Phase 1 / Phase 2 | 2020-02-04 |
| Terminated | Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disea Acute Graft-versus-host Disease | Phase 1 / Phase 2 | 2019-12-31 |
| Terminated | Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FI Advanced or Metastatic Solid Tumors, FGFR Mutations, FGFR Translocations | Phase 2 | 2019-10-31 |
| Terminated | Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectabl Solid Tumor Malignancy | Phase 2 | 2019-10-17 |
| Completed | Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) Non-segmental Vitiligo | Phase 3 | 2019-10-03 |
| Terminated | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | 2019-09-25 |
| Completed | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) Non-segmental Vitiligo | Phase 3 | 2019-09-20 |
| Withdrawn | INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) Advanced and/or Metastatic Solid Tumors, Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer, Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma | Phase 1 | 2019-07-15 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic C Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 3 | 2019-06-03 |
| Completed | A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis Atopic Dermatitis | Phase 1 | 2019-05-30 |
| Withdrawn | A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris Pemphigus Vulgaris | Phase 2 | 2019-03-01 |
| Completed | A Study of INCB050465 in Primary Sjögren's Syndrome Primary Sjögren's Syndrome | Phase 2 | 2019-02-28 |
| Completed | A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) Metastatic Merkel Cell Carcinoma | Phase 2 | 2019-02-25 |
| Terminated | GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Chronic Graft-versus-host Disease | Phase 2 / Phase 3 | 2019-01-17 |
| Completed | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Metastatic Non-small Cell Lung Cancer, Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer | Phase 2 | 2019-01-09 |
| Completed | Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxol Atopic Dermatitis | Phase 3 | 2018-12-20 |
| Completed | TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis Atopic Dermatitis | Phase 3 | 2018-12-20 |
| Completed | A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participan Solid Tumors | Phase 1 | 2018-12-10 |
| Completed | A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | 2018-12-03 |
| Completed | A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia Autoimmune Hemolytic Anemia | Phase 2 | 2018-11-21 |
| Completed | A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Hidradenitis Suppurativa | Phase 2 | 2018-10-15 |
| Completed | A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-2 Squamous Cell Carcinoma of Anal Canal | Phase 2 | 2018-10-08 |
| Completed | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Cervical Cancer, Gastric Cancer, Stomach Cancer | Phase 1 | 2018-09-24 |
| Withdrawn | A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis Moderate to Severe Ulcerative Colitis | Phase 2 | 2018-09-20 |
| Terminated | A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies Advanced Solid Tumors | Phase 1 | 2018-08-27 |
| Completed | INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors Unresectable or Metastatic Solid Tumors | Phase 1 | 2018-08-17 |
| Completed | A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111) Lymphoma | Phase 1 | 2018-08-02 |
| Completed | A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Hidradenitis Suppurativa | Phase 2 | 2018-07-17 |
| Completed | INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previo B-cell Lymphoma | Phase 1 | 2018-07-02 |
| Terminated | A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma Relapsed Ewing Sarcoma | Phase 1 | 2018-06-27 |
| Terminated | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Met Solid Tumors | Phase 1 / Phase 2 | 2018-03-21 |
| Completed | Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Hos Acute Graft-versus-host Disease | Phase 1 | 2018-03-20 |
| Completed | A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma Lymphoma | Phase 2 | 2018-03-14 |
| Terminated | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or W Solid Tumors | Phase 1 / Phase 2 | 2018-03-01 |
| Terminated | GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Hematologic Malignancies | Phase 1 | 2018-02-27 |
| Completed | A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Pa MPN (Myeloproliferative Neoplasms) | Phase 2 | 2018-01-26 |
| Completed | A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum- Lung Cancer | Phase 2 | 2018-01-09 |
| Terminated | Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Lung Cancer | Phase 3 | 2017-12-27 |
| Completed | Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carci UC (Urothelial Cancer) | Phase 3 | 2017-12-22 |
| Completed | A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) Lymphoma | Phase 2 | 2017-12-18 |
| Completed | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE Lung Cancer | Phase 2 | 2017-12-15 |
| Withdrawn | Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcin Head and Neck Cancer | Phase 3 | 2017-12-15 |
| Completed | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) Renal Cell Carcinoma (RCC) | Phase 3 | 2017-12-07 |
| Completed | Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE UC (Urothelial Cancer) | Phase 3 | 2017-12-04 |
| Completed | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Cancer | Phase 3 | 2017-12-01 |
| Completed | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer | Phase 1 / Phase 2 | 2017-11-21 |
| Completed | A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Brut Lymphoma | Phase 2 | 2017-11-20 |
| Terminated | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to MPN (Myeloproliferative Neoplasms) | Phase 2 | 2017-11-14 |
| Completed | A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis Atopic Dermatitis | Phase 1 | 2017-09-21 |
| Completed | A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) Solid Tumors | Phase 1 | 2017-08-01 |
| Completed | GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graf Graft-versus-host Disease (GVHD) | Phase 3 | 2017-07-19 |
| Completed | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. H Graft-versus-host Disease (GVHD) | Phase 3 | 2017-06-29 |
| Completed | A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo Vitiligo | Phase 2 | 2017-06-07 |
| Terminated | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma a Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Esophageal Cancer | Phase 1 | 2017-05-25 |
| Completed | A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Met Solid Tumor | Phase 1 / Phase 2 | 2017-05-02 |
| Completed | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neop MPN (Myeloproliferative Neoplasms) | Phase 2 | 2017-04-25 |
| Terminated | A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cel Sickle Cell Disease | Phase 1 | 2017-04-20 |
| Completed | A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | 2017-03-02 |
| Terminated | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Solid Tumors, Advanced Malignancies, Metastatic Cancer | Phase 1 / Phase 2 | 2017-02-27 |
| Completed | Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Lymphoma | Phase 1 | 2017-02-15 |
| Terminated | A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis MPN (Myeloproliferative Neoplasms) | Phase 2 | 2017-02-08 |
| Completed | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangioca Cholangiocarcinoma | Phase 2 | 2017-01-16 |
| Completed | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma UC (Urothelial Cancer) | Phase 2 | 2017-01-12 |
| Completed | A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With At Atopic Dermatitis | Phase 2 | 2017-01-09 |
| Completed | Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) MPN (Myeloproliferative Neoplasms) | — | 2016-12-31 |
| Completed | A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Graft-versus-host Disease (GVHD) | Phase 2 | 2016-12-30 |
| Completed | A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffu Lymphoma | Phase 1 / Phase 2 | 2016-12-29 |
| Completed | An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lu Lung Cancer | Phase 1 / Phase 2 | 2016-12-20 |
| Active Not Recruiting | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxoli Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer | Phase 2 | 2016-11-30 |
| Completed | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | 2016-11-28 |
| Completed | A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | 2016-11-15 |
| Completed | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Leukemia | Phase 2 | 2016-09-30 |
| Completed | A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjec B-Cell Malignancies | Phase 1 / Phase 2 | 2016-09-22 |
| Completed | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC) | Phase 1 | 2016-09-14 |
| Completed | A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma Melanoma | Phase 3 | 2016-06-21 |
| Terminated | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies Solid Tumors | Phase 1 / Phase 2 | 2016-05-18 |
| Terminated | An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancie Solid Tumors and Hematologic Malignancy | Phase 1 / Phase 2 | 2016-05-05 |
| Completed | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Colorectal Cancer (CRC), Endometrial Cancer, Melanoma | Phase 1 | 2016-01-25 |
| Terminated | Study of INCB053914 in Subjects With Advanced Malignancies Solid Tumors | Phase 1 / Phase 2 | 2015-12-29 |
| Completed | Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD Graft-versus-host Disease (GVHD) | Phase 1 | 2015-12-01 |
| Terminated | A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA) Alopecia Areata | Phase 2 | 2015-11-18 |
| Terminated | Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors Solid Tumors | Phase 1 | 2015-11-01 |
| Terminated | INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma | Phase 2 | 2015-06-01 |
| Terminated | An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies Solid Tumors and Hematologic Malignancy | Phase 1 / Phase 2 | 2015-04-14 |
| Terminated | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Lung Cancer, Solid Tumor, Gastric Cancer | Phase 1 / Phase 2 | 2015-02-27 |
| Completed | A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanc Solid Tumors, Head and Neck Cancer, Lung Cancer | Phase 1 / Phase 2 | 2015-01-05 |
| Completed | Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. Philadelphia Positive, BCR-ABL Positive, Acute Lymphoblastic Leukemia | Phase 2 | 2014-12-04 |
| Withdrawn | Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor R Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma) | Phase 2 | 2014-12-01 |
| Completed | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer | Phase 1 / Phase 2 | 2014-11-26 |
| Terminated | A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously T NSCLC (Non-small Cell Lung Carcinoma), UC (Urothelial Cancer) | Phase 1 | 2014-11-01 |
| Terminated | An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies Solid Tumors, Advanced Malignancies, Metastatic Cancer | Phase 1 / Phase 2 | 2014-09-10 |
| Terminated | Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer NSCLC (Non-small Cell Lung Carcinoma) | Phase 2 | 2014-09-01 |
| Completed | Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) MPN (Myeloproliferative Neoplasms) | — | 2014-07-31 |
| Completed | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participan Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer | Phase 1 / Phase 2 | 2014-07-17 |
| Terminated | A Study of Ruxolitinib in Pancreatic Cancer Patients Pancreatic Cancer | Phase 3 | 2014-06-01 |
| Terminated | INCB047986 in Rheumatoid Arthritis Rheumatoid Arthritis | Phase 2 | 2014-05-01 |
| Terminated | A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer | Phase 2 | 2014-05-01 |
| Terminated | Study of Ruxolitinib in Colorectal Cancer Patients CRC (Colorectal Cancer) | Phase 2 | 2014-03-01 |
| Terminated | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) Pancreatic Cancer | Phase 3 | 2014-03-01 |
| Terminated | Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer NSCLC (Non-small Cell Lung Carcinoma) | Phase 2 | 2014-02-11 |
| Terminated | Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS) MDS (Myelodysplastic Syndrome) | Phase 1 / Phase 2 | 2014-01-01 |
| Terminated | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Solid Tumor, Hodgkin's Lymphoma, NHL (Non-Hodgkin Lymphoma) | Phase 1 | 2013-09-01 |
| Active Not Recruiting | Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies B-cell Malignancies | Phase 1 | 2013-06-30 |
| Completed | Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Ad Solid Tumors, Pancreatic Cancer | Phase 1 / Phase 2 | 2013-06-01 |
| Terminated | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors Solid Tumors, Pancreatic Cancer | Phase 1 | 2013-04-01 |
| Terminated | A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only Ovarian Cancer, Genitourinary (GU) Tumors | Phase 2 | 2012-08-01 |
| Completed | An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis MPN (Myeloproliferative Neoplasms) | Phase 2 | 2012-07-16 |
| Completed | A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis Plaque Psoriasis | Phase 2 | 2012-06-01 |
| Completed | Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief S Polycythemia Vera | Phase 3 | 2012-06-01 |
| Terminated | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Pla Melanoma | Phase 1 / Phase 2 | 2012-03-01 |
| Completed | A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day C Rheumatoid Arthritis | Phase 2 | 2012-03-01 |
| Completed | Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis | Phase 2 | 2011-09-01 |
| Completed | Study of Ruxolitinib in Pancreatic Cancer Patients Pancreatic Cancer | Phase 2 | 2011-07-01 |
| Completed | Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myel MPN (Myeloproliferative Neoplasms) | Phase 2 | 2011-06-15 |
| Completed | Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post- Myelofibrosis | Phase 1 | 2011-03-31 |
| Completed | Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients Myelofibrosis | Phase 2 | 2011-03-01 |
| Completed | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: Polycythemia Vera | Phase 3 | 2010-10-27 |
| Terminated | Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Ca Breast Cancer | Phase 1 / Phase 2 | 2010-10-01 |
| Completed | A Dose-escalation Study in Subjects With Advanced Malignancies Solid Tumors and Hematologic Malignancy | Phase 1 | 2010-07-01 |
| Completed | A Dose-escalation Study in Subjects With Advanced Malignancies Solid Tumor, Advanced Cancer, Metastatic Cancer | Phase 1 | 2010-01-01 |
| Completed | COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial MPN (Myeloproliferative Neoplasms) | Phase 3 | 2009-08-01 |
| Completed | INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Re Rheumatoid Arthritis | Phase 2 | 2009-05-01 |
| Completed | A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Pso Psoriasis | Phase 2 | 2008-10-28 |
| Terminated | Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Throm Myeloproliferative Neoplasm (MPN) | Phase 2 | 2008-08-20 |
| Completed | Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Dia Type 2 Diabetes | Phase 2 | 2008-05-01 |
| Terminated | Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Di Type 2 Diabetes | Phase 2 | 2008-05-01 |
| Completed | A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424 Multiple Myeloma | Phase 2 | 2008-03-01 |
| Terminated | Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostat Prostate Cancer | Phase 2 | 2008-02-01 |
| Completed | A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Acti Rheumatoid Arthritis | Phase 2 | 2007-10-01 |
| Completed | Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis Psoriasis | Phase 2 | 2007-08-31 |
| Terminated | Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive M Breast Cancer | Phase 1 / Phase 2 | 2007-07-01 |
| Completed | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thromb Myelofibrosis, Polycythemia Vera, Thrombocytosis | Phase 1 / Phase 2 | 2007-06-01 |
| Completed | A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis Psoriasis | Phase 2 | 2007-05-31 |
| Completed | Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects Diabetes Mellitus, Type 2, Obesity | Phase 2 | 2007-04-01 |
| Completed | A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabe Insulin Resistance, Obesity | Phase 1 | 2006-11-01 |
| Completed | Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Pat HIV Infections | Phase 2 | 2006-10-01 |
| Terminated | Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance HIV Infections, Human Immunodeficiency Virus | Phase 2 | 2006-04-01 |
| Completed | Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors Solid Tumors and Hematologic Malignancy | Phase 1 | 2005-01-01 |
| Available | An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin an Squamous Cell Carcinoma of the Anal Canal | — | — |
| No Longer Available | Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia Aplastic Anemia | — | — |
| Approved For Marketing | Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD Graft-versus-host Disease (GVHD) | — | — |
| Approved For Marketing | An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Graft-versus-host Disease (GVHD) | — | — |
| Available | Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease STAT1 Gain-of-Function Disease | — | — |
| No Longer Available | Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis | — | — |
| No Longer Available | Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection COVID-19 | — | — |
| No Longer Available | Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer | — | — |
| Available | Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD) Chronic Graft Vs. Host Disease | — | — |
| No Longer Available | Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma | — | — |